1
|
Lacroix C, Guilhaumou R, Micallef J, Bruneteau G, Desnuelle C, Blin O. Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients' view? Rev Neurol (Paris) 2023; 179:967-974. [PMID: 37460332 DOI: 10.1016/j.neurol.2023.03.018] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 12/19/2022] [Accepted: 03/13/2023] [Indexed: 11/12/2023]
Abstract
Cannabis may have therapeutic benefits to relieve symptoms of amyotrophic lateral sclerosis (ALS) thanks to its pleiotropic pharmacological activity. This study is the first to present a large questionnaire-based survey about the "real-life" situation regarding cannabis use in the medical context in ALS patients in France. There were 129 respondents and 28 reported the use of cannabis (21.7%) to relieve symptoms of ALS. Participants mostly reported the use of cannabidiol (CBD) oil and cannabis weed and declared benefits both on motor (rigidity, cramps, fasciculations) and non-motor (sleep quality, pain, emotional state, quality of life, depression) symptoms and only eight reported minor adverse reactions (drowsiness, euphoria and dry mouth). Even if cannabis is mostly used outside medical pathways and could expose patients to complications (street and uncontrolled drugs, drug-drug interactions, adverse effects…), most of the participants reported "rational" consumption (legal cannabinoids, with only few combustion and adverse reactions). Despite some limitations, this study highlights the need for further research on the potential benefits of cannabis use for the management of ALS motor and non-motor symptoms. Indeed, there is an urgent need and call for and from patients to know more about cannabis and secure its use in a medical context.
Collapse
Affiliation(s)
- C Lacroix
- Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France.
| | - R Guilhaumou
- Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France
| | - J Micallef
- Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France
| | - G Bruneteau
- Paris ALS expert center, Assistance publique-Hôpitaux de Paris, Sorbonne université, Pitié-Salpêtrière Hospital, 75013 Paris, France; Brain Institute, Pitié-Salpêtrière Hospital, 75013 Paris, France
| | - C Desnuelle
- Departement of Neurology, Charity Association ARSLA, Emeritus Professor University Côte d'Azur, Côte d'Azur, France
| | - O Blin
- Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM, Inserm, Inst Neurosci Syst, UMR 1106, Aix-Marseille University, University Hospital Federation DHUNE, 13005 Marseille, France
| |
Collapse
|
2
|
Neumann A, Ohlei O, Küçükali F, Bos IJ, Timsina J, Vos S, Prokopenko D, Tijms BM, Andreasson U, Blennow K, Vandenberghe R, Scheltens P, Teunissen CE, Engelborghs S, Frisoni GB, Blin O, Richardson JC, Bordet R, Lleó A, Alcolea D, Popp J, Marsh TW, Gorijala P, Clark C, Peyratout G, Martinez-Lage P, Tainta M, Dobson RJB, Legido-Quigley C, Van Broeckhoven C, Tanzi RE, Ten Kate M, Lill CM, Barkhof F, Cruchaga C, Lovestone S, Streffer J, Zetterberg H, Visser PJ, Sleegers K, Bertram L. Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning. Genome Med 2023; 15:79. [PMID: 37794492 PMCID: PMC10548686 DOI: 10.1186/s13073-023-01233-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 09/12/2023] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Genome-wide association studies (GWAS) of Alzheimer's disease (AD) have identified several risk loci, but many remain unknown. Cerebrospinal fluid (CSF) biomarkers may aid in gene discovery and we previously demonstrated that six CSF biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and neurogranin) cluster into five principal components (PC), each representing statistically independent biological processes. Here, we aimed to (1) identify common genetic variants associated with these CSF profiles, (2) assess the role of associated variants in AD pathophysiology, and (3) explore potential sex differences. METHODS We performed GWAS for each of the five biomarker PCs in two multi-center studies (EMIF-AD and ADNI). In total, 973 participants (n = 205 controls, n = 546 mild cognitive impairment, n = 222 AD) were analyzed for 7,433,949 common SNPs and 19,511 protein-coding genes. Structural equation models tested whether biomarker PCs mediate genetic risk effects on AD, and stratified and interaction models probed for sex-specific effects. RESULTS Five loci showed genome-wide significant association with CSF profiles, two were novel (rs145791381 [inflammation] and GRIN2D [synaptic functioning]) and three were previously described (APOE, TMEM106B, and CHI3L1). Follow-up analyses of the two novel signals in independent datasets only supported the GRIN2D locus, which contains several functionally interesting candidate genes. Mediation tests indicated that variants in APOE are associated with AD status via processes related to amyloid and tau pathology, while markers in TMEM106B and CHI3L1 are associated with AD only via neuronal injury/inflammation. Additionally, seven loci showed sex-specific associations with AD biomarkers. CONCLUSIONS These results suggest that pathway and sex-specific analyses can improve our understanding of AD genetics and may contribute to precision medicine.
Collapse
Affiliation(s)
- Alexander Neumann
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Olena Ohlei
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Ratzeburger Allee 160, V50.2M, Lübeck, 23562, Germany
| | - Fahri Küçükali
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Isabelle J Bos
- Netherlands Institute for Health Services Research, Utrecht, Netherlands
| | - Jigyasha Timsina
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
- NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA
| | - Stephanie Vos
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands
| | - Dmitry Prokopenko
- Genetics and Aging Unit and McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
| | - Betty M Tijms
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Ulf Andreasson
- Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
- Neurology Service, University Hospital Leuven, Leuven, Belgium
| | - Philip Scheltens
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Charlotte E Teunissen
- Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands
| | - Sebastiaan Engelborghs
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Department of Neurology and Memory Clinic, Universitair Ziekenhuis Brussel (UZ Brussel) and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Giovanni B Frisoni
- Memory Center, Department of Rehabilitation and Geriatrics, Geneva University and University Hospitals, Geneva, Switzerland
| | - Oliver Blin
- Clinical Pharmacology & Pharmacovigilance Department, Marseille University Hospital, Marseille, France
| | | | - Régis Bordet
- Neuroscience & Cognition, CHU de Lille, University of Lille, Inserm, France
| | - Alberto Lleó
- Memory Unit, Neurology Department, Hospital de Sant Pau, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Daniel Alcolea
- Memory Unit, Neurology Department, Hospital de Sant Pau, Barcelona, Spain
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Julius Popp
- Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zürich, Zurich, Switzerland
- Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
| | - Thomas W Marsh
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
- NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA
- Division of Biology & Biomedical Sciences, Washington University in St. Louis, St Louis, MO, USA
| | - Priyanka Gorijala
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
- NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA
| | - Christopher Clark
- Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zürich, Zurich, Switzerland
| | - Gwendoline Peyratout
- Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
| | - Pablo Martinez-Lage
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Mikel Tainta
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain
- Zumarraga Hospital, Osakidetza, Integrated Health Organization (OSI) Goierri-Urola Garia, Basque Country, Spain
| | - Richard J B Dobson
- Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Boston, UK
- NIHR BioResource Centre Maudsley, NIHR Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust (SLaM) & Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, UK
- Health Data Research UK London, University College London, London, UK
- Institute of Health Informatics, University College London, London, UK
- The National Institute for Health Research University College London Hospitals Biomedical Research Centre, University College London, London, UK
| | - Cristina Legido-Quigley
- Steno Diabetes Center, Copenhagen, Denmark
- Institute of Pharmaceutical Science, King's College London, London, UK
| | - Christine Van Broeckhoven
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Rudolph E Tanzi
- Genetics and Aging Unit and McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
| | - Mara Ten Kate
- Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
| | - Christina M Lill
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Ratzeburger Allee 160, V50.2M, Lübeck, 23562, Germany
- Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
- Ageing Epidemiology Research Unit, School of Public Health, Imperial College, London, UK
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands
- Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London, UK
| | - Carlos Cruchaga
- Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
- NeuroGenomics and Informatics Center, Washington University School of Medicine, St Louis, MO, USA
- Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO, USA
| | - Simon Lovestone
- Janssen Medical Ltd, Wycombe, UK
- Department of Psychiatry, University of Oxford, Oxford, UK
| | - Johannes Streffer
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- AC Immune SA, Lausanne, Switzerland
- Janssen R&D, LLC, Beerse, Belgium
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK
- UK Dementia Research Institute, University College London, London, UK
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
| | - Pieter Jelle Visser
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, Netherlands
- Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, Netherlands
| | - Kristel Sleegers
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Lars Bertram
- Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Ratzeburger Allee 160, V50.2M, Lübeck, 23562, Germany.
- Centre for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway.
| |
Collapse
|
3
|
Küçükali F, Neumann A, Van Dongen J, De Pooter T, Joris G, De Rijk P, Ohlei O, Dobricic V, Bos I, Vos SJB, Engelborghs S, De Roeck E, Vandenberghe R, Gabel S, Meersmans K, Tsolaki M, Verhey F, Martinez‐Lage P, Tainta M, Frisoni G, Blin O, Richardson JC, Bordet R, Scheltens P, Popp J, Peyratout G, Johannsen P, Frölich L, Freund‐Levi Y, Streffer J, Lovestone S, Legido‐Quigley C, Kate MT, Barkhof F, Zetterberg H, Bertram L, Strazisar M, Visser PJ, Van Broeckhoven C, Sleegers K. Whole‐exome rare‐variant analysis of Alzheimer's disease and related biomarker traits. Alzheimers Dement 2022. [DOI: 10.1002/alz.12842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 09/16/2022] [Accepted: 09/28/2022] [Indexed: 12/08/2022]
|
4
|
Neumann A, Küçükali F, Bos I, Vos SJB, Engelborghs S, De Pooter T, Joris G, De Rijk P, De Roeck E, Tsolaki M, Verhey F, Martinez-Lage P, Tainta M, Frisoni G, Blin O, Richardson J, Bordet R, Scheltens P, Popp J, Peyratout G, Johannsen P, Frölich L, Vandenberghe R, Freund-Levi Y, Streffer J, Lovestone S, Legido-Quigley C, Ten Kate M, Barkhof F, Strazisar M, Zetterberg H, Bertram L, Visser PJ, van Broeckhoven C, Sleegers K. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Mol Psychiatry 2022; 27:1990-1999. [PMID: 35173266 PMCID: PMC9126805 DOI: 10.1038/s41380-022-01437-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 11/04/2021] [Accepted: 01/05/2022] [Indexed: 11/30/2022]
Abstract
Alzheimer's disease (AD) biomarkers represent several neurodegenerative processes, such as synaptic dysfunction, neuronal inflammation and injury, as well as amyloid pathology. We performed an exome-wide rare variant analysis of six AD biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and Neurogranin) to discover genes associated with these markers. Genetic and biomarker information was available for 480 participants from two studies: EMIF-AD and ADNI. We applied a principal component (PC) analysis to derive biomarkers combinations, which represent statistically independent biological processes. We then tested whether rare variants in 9576 protein-coding genes associate with these PCs using a Meta-SKAT test. We also tested whether the PCs are intermediary to gene effects on AD symptoms with a SMUT test. One PC loaded on NfL and YKL-40, indicators of neuronal injury and inflammation. Four genes were associated with this PC: IFFO1, DTNB, NLRC3, and SLC22A10. Mediation tests suggest, that these genes also affect dementia symptoms via inflammation/injury. We also observed an association between a PC loading on Neurogranin, a marker for synaptic functioning, with GABBR2 and CASZ1, but no mediation effects. The results suggest that rare variants in IFFO1, DTNB, NLRC3, and SLC22A10 heighten susceptibility to neuronal injury and inflammation, potentially by altering cytoskeleton structure and immune activity disinhibition, resulting in an elevated dementia risk. GABBR2 and CASZ1 were associated with synaptic functioning, but mediation analyses suggest that the effect of these two genes on synaptic functioning is not consequential for AD development.
Collapse
Affiliation(s)
- Alexander Neumann
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
| | - Fahri Küçükali
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Isabelle Bos
- Netherlands Institute for Health Services Research, Utrecht, the Netherlands
| | - Stephanie J B Vos
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands
| | - Sebastiaan Engelborghs
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Department of Neurology and Memory Clinic, Universitair Ziekenhuis Brussel (UZ Brussel) and Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - Tim De Pooter
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Geert Joris
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Peter De Rijk
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Ellen De Roeck
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium
| | - Magda Tsolaki
- 1st Department of Neurology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Thessaloniki, Greece
| | - Frans Verhey
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands
- Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, the Netherlands
- School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
| | - Pablo Martinez-Lage
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Mikel Tainta
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Giovanni Frisoni
- Department of Psychiatry, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland
- RCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Oliver Blin
- Clinical Pharmacology & Pharmacovigilance Department, Marseille University Hospital, Marseille, France
| | - Jill Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevanage, UK
| | - Régis Bordet
- Neuroscience & Cognition, CHU de Lille, University of Lille, Inserm, France
| | - Philip Scheltens
- Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
| | - Julius Popp
- Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland
- Old Age Psychiatry, Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
| | - Gwendoline Peyratout
- Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
| | - Peter Johannsen
- Clinical Drug Development, Novo Nordisk, Copenhagen, Denmark
| | - Lutz Frölich
- Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Rik Vandenberghe
- Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
| | - Yvonne Freund-Levi
- Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Karolinska Institute Stockholm Sweden, Stockholm, Sweden
- School of Medical Sciences Örebro, University Örebro, Örebro, Sweden
| | - Johannes Streffer
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - Simon Lovestone
- Department of Psychiatry, University of Oxford, Oxford, UK
- Janssen Medical Ltd, High Wycombe, UK
| | - Cristina Legido-Quigley
- Steno Diabetes Center, Copenhagen, Denmark
- Institute of Pharmaceutical Sciences, King's College London, London, UK
| | - Mara Ten Kate
- Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Institutes of Neurology and Healthcare Engineering, University College London, London, UK
| | - Mojca Strazisar
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neuromics Support Facility, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
- Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
- UK Dementia Research Institute, University College London, London, UK
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
| | - Lars Bertram
- Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany
- Centre for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway
| | - Pieter Jelle Visser
- Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands
- Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, the Netherlands
| | - Christine van Broeckhoven
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- Neurodegenerative Brain Diseases Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
| | - Kristel Sleegers
- Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| |
Collapse
|
5
|
Péran P, Salabert AS, Dondaine T, Leclerc X, Gros-Dagnac H, Ranjeva JP, Lopes R, Lanteaume L, Blin O, Thalamas C, Bordet R, Payoux P. Functional connectivity and cognitive changes after donepezil treatment in healthy participants. Psychopharmacology (Berl) 2021; 238:3071-3082. [PMID: 34370064 DOI: 10.1007/s00213-021-05923-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Accepted: 07/06/2021] [Indexed: 10/20/2022]
Abstract
RATIONALE Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated. OBJECTIVES The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers. METHODS The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design. RESULTS Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition. CONCLUSIONS In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.
Collapse
Affiliation(s)
- P Péran
- Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France.
| | - A S Salabert
- Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France
| | - T Dondaine
- Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France
| | - X Leclerc
- Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France
| | - H Gros-Dagnac
- Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France
| | - J-P Ranjeva
- Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France
| | - R Lopes
- Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France
| | - L Lanteaume
- Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.,Department of Clinical Pharmacology (UPCET), Aix-Marseille University-INSERM-Timone University Hospital, Marseille, France
| | - O Blin
- Centre for Metabolic Exploration by Magnetic Resonance (CEMEREM), Aix-Marseille University-CNRS-CRMBM-Timone University Hospital, Marseille, France.,Department of Clinical Pharmacology (UPCET), Aix-Marseille University-INSERM-Timone University Hospital, Marseille, France
| | - C Thalamas
- Clinical Investigation Center (CIC1436), Toulouse, France
| | - R Bordet
- Degenerative & Vascular Cognitive Disorders Research Unit, INSERM-Lille University-Lille University Hospital, Lille, France
| | - P Payoux
- Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France
| | | |
Collapse
|
6
|
Marsot A, Hraiech S, Cassir N, Daviet F, Parzy G, Blin O, Papazian L, Guilhaumou R. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens? Int J Antimicrob Agents 2020; 56:106124. [PMID: 32739478 DOI: 10.1016/j.ijantimicag.2020.106124] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Revised: 06/17/2020] [Accepted: 07/23/2020] [Indexed: 12/20/2022]
Abstract
Modifications of antibiotic pharmacokinetic parameters have been reported in critically ill patients, resulting in a risk of treatment failure. We aimed to determine optimised amikacin (AMK), gentamicin (GEN) and tobramycin (TOB) intravenous dosing regimens in this patient population. Patients admitted to the medical ICU and treated with AMK, GEN or TOB were included. Analyses were performed using a parametric population approach. Monte Carlo simulations were performed and the probability of target attainment (PTA) was calculated using Cmax/MIC ≥ 8 and trough concentrations as targets. A total of 117 critically ill hospitalised patients were studied. Median values (interindividual variability, ɷ2) of clearance were 3.51 (0.539), 3.53 (0.297), 2.70 (0.339) and 5.07 (0.339) L/h for AMK, GEN, TOB, and TOB in cystic fibrosis (CF), respectively. Median values (ɷ2) of central volume of distribution were 30.2 (0.215), 20.0 (0.109) and 25.6 (0.177) L for AMK, GEN and TOB, respectively. Simulations showed that doses should be adjusted to actual body weight and creatinine clearance (CLCR) for AMK and GEN, and according to CLCR and presence of CF for TOB. In conclusion, our recommendations for treating Pseudomonas aeruginosa infections in this population include using initial doses of 35 mg/kg for AMK or 10 mg/kg for TOB (CF and non-CF patients). GEN demonstrated the best rates of target attainment against Staphylococcus aureus infections with a dose of 5 mg/kg. As high aminoglycoside doses are required in this population, efficacy and safety targets are conflicting and therapeutic drug monitoring remains an important tool to manage this issue.
Collapse
Affiliation(s)
- A Marsot
- Faculté de Pharmacie, Université de Montréal, Montréal, Canada.
| | - S Hraiech
- Service de Médecine Intensive-Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS-Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France
| | - N Cassir
- Aix-Marseille Université, IRD, APHM, MEPHI, Marseille, France; IHU Méditerranée Infection, Marseille, France
| | - F Daviet
- Service de Médecine Intensive-Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS-Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France
| | - G Parzy
- Service de Médecine Intensive-Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS-Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France
| | - O Blin
- IHU Méditerranée Infection, Marseille, France
| | - L Papazian
- Service de Médecine Intensive-Réanimation, APHM, Hôpital Nord, Marseille, France; CEReSS-Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France
| | - R Guilhaumou
- Aix-Marseille Univ., APHM, INSERM, CIC CPCET Service de Pharmacologie Clinique et Pharmacovigilance, INS Inst Neurosci Syst, Marseille, France
| |
Collapse
|
7
|
Wang YL, Guilhaumou R, Blin O, Velly L, Marsot A. External evaluation of population pharmacokinetic models for continuous administration of meropenem in critically ill adult patients. Eur J Clin Pharmacol 2020; 76:1281-1289. [PMID: 32495084 DOI: 10.1007/s00228-020-02922-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Accepted: 05/29/2020] [Indexed: 12/30/2022]
Abstract
PURPOSE Beta-lactams (BL), the most commonly prescribed class of antibiotics, are recommended as the first-line therapy for multiple indications in infectious disease guidelines. Meropenem (MERO) is frequently used in intensive care units (ICU) to treat bacterial infections with or without sepsis. The pharmacokinetics of MERO display a large variability in patients admitted to ICUs due to altered pathophysiology. The aim of this study was to perform an external evaluation of published population pharmacokinetic models of MERO in order to test their predictive performance in a cohort of ICU adult patients. METHODS A literature search in PubMed/Medline database was made following the PRISMA statement. External evaluation was performed using NONMEM software, and the bias and inaccuracy values were calculated. RESULTS An external validation dataset from the Timone Hospital in Marseille, France, included 84 concentration samples from 27 patients. Four models of MERO were identified according to the inclusion criteria of the study. None of the models presented acceptable values of bias and inaccuracy. CONCLUSION While performing external evaluations on some populations may confirm a model's suitability to diverse groups of patients, there is still some variability that cannot be explained nor solved by the procedure. This brings to light the difficulty to develop only one model for ICU patients and the need to develop one specific model to each population of critically ill patients.
Collapse
Affiliation(s)
- Y L Wang
- Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculté de Pharmacie, Université de Montréal, Pavillon Jean-Coutu, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada.,Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada
| | - R Guilhaumou
- Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.,Pharmacologie intégrée et interface clinique et industrielle, Institut de Neuroscience des systèmes, CNRS 7289, Aix Marseille Université, 13385, Marseille, France
| | - O Blin
- Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.,Pharmacologie intégrée et interface clinique et industrielle, Institut de Neuroscience des systèmes, CNRS 7289, Aix Marseille Université, 13385, Marseille, France
| | - L Velly
- Service d'Anesthésie-Réanimation, Hôpital de la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - Amélie Marsot
- Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculté de Pharmacie, Université de Montréal, Pavillon Jean-Coutu, 2940 chemin de Polytechnique, Montréal, QC, H3T 1J4, Canada. .,Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada. .,Centre de Recherche, CHU Sainte Justine, Montréal, QC, Canada.
| |
Collapse
|
8
|
Ansari A, Maffioletti E, Milanesi E, Marizzoni M, Frisoni GB, Blin O, Richardson JC, Bordet R, Forloni G, Gennarelli M, Bocchio-Chiavetto L. miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2019; 82:102-109. [PMID: 31437718 DOI: 10.1016/j.neurobiolaging.2019.06.005] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 06/12/2019] [Accepted: 06/12/2019] [Indexed: 12/22/2022]
Abstract
The identification of mechanisms associated with Alzheimer's disease (AD) development in mild cognitive impairment (MCI) would be of great usefulness to clarify AD pathogenesis and to develop preventive and therapeutic strategies. In this study, blood levels of the candidate microRNAs (small noncoding RNAs that play a pivotal role in gene expression) miR-146a, miR-181a, miR-181b, miR-24-3p, miR-186a, miR-101, miR-339, miR-590, and miR-22 have been investigated for association to AD conversion within 2 years in a group of 45 patients with MCI. Baseline miR-146a (p = 0.036) and miR-181a (p = 0.026) showed a significant upregulation in patients with MCI who later converted to AD. These alterations were related to AD hallmarks: a significant negative correlation was found with amyloid beta cerebrospinal fluid concentration for miR-146a (p = 0.006) and miR-181a (p = 0.001). Moreover, higher levels of miR-146a were associated to apolipoprotein E ε4 allele presence, smaller volume of the hippocampus (p = 0.045) and of the CA1 (p = 0.013) and the subiculum (p = 0.027) subfields. Increased levels of miR-146a (p = 0.031) and miR-181a (p = 0.002) were also linked with diffusivity alterations in the cingulum. These data support a role for miR-146a and miR-181a in the mechanisms of AD progression.
Collapse
Affiliation(s)
- Abulaish Ansari
- Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Elisabetta Maffioletti
- Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Elena Milanesi
- Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Cellular and Molecular Medicine, 'Victor Babes' National Institute of Pathology, Bucharest, Romania
| | - Moira Marizzoni
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Giovanni B Frisoni
- Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneve, Geneve, Switzerland
| | - Oliver Blin
- AP-HM, CHU Timone, CIC CPCET, Service de Pharmacologie Clinique et Pharmacovigilance, Marseille, France
| | - Jill C Richardson
- Neurosciences Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK; MRL UK, MSD, 2 Royal College Street, London, UK
| | - Regis Bordet
- U1171 Inserm, CHU Lille, Degenerative and Vascular Cognitive Disorders, University of Lille, Lille, France
| | - Gianluigi Forloni
- Neuroscience Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy
| | - Massimo Gennarelli
- Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
| | - Luisella Bocchio-Chiavetto
- Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Faculty of Psychology, eCampus University, Novedrate (Como), Italy
| | | |
Collapse
|
9
|
Gaillard-Bigot F, Zendjidjian XY, Kheloufi F, Casse-Perrot C, Guilhaumou R, Micallef J, Fakra E, Azorin JM, Blin O. Quantitative System Pharmacology (QSP): An Integrative Framework for paradigm change in the treatment of the first-episode schizophrenia. Encephale 2019; 44:S34-S38. [PMID: 30935485 DOI: 10.1016/s0013-7006(19)30077-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Despite the lack of progress in the curative treatment of mental illness, especially schizophrenia, the accumulation of neuroscience data over the past decade suggests the re-conceptualization of schizophrenia. With the advent of new biomarkers and cognitive tools, new neuroscience technologies such as functional dynamic connectivity and the identification of subtle clinical features; it is now possible to detect early stages at risk or prodromes of a first psychotic episode. Current concepts reconceptualizes schizophrenia as a neurodevelopmental disorder at early onset, with polygenic risk and only symptomatic treatment for positive symptoms at this time. The use of such technologies in the future suggests new diagnostic and therapeutic options. Next steps include new pharmacological perspectives and potential contributions of new technologies such as quantitative system pharmacology brain computational modeling approach.
Collapse
Affiliation(s)
- F Gaillard-Bigot
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France
| | - X-Y Zendjidjian
- Pôle psychiatrie centre, hôpital de la Conception, assistance publique des hôpitaux de Marseille, Marseille, France
| | - F Kheloufi
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France
| | - C Casse-Perrot
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France
| | - R Guilhaumou
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France
| | - J Micallef
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France
| | - E Fakra
- Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France, Inserm U1059, University of Lyon, Saint-Etienne F-42023, France
| | - J-M Azorin
- Department of Psychiatry, Sainte Marguerite University Hospital, Marseille, France
| | - O Blin
- Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France.
| |
Collapse
|
10
|
Marsot A, Gallais F, Galambrun C, Coze C, Blin O, Andre N, Guilhaumou R. Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens. Paediatr Drugs 2018; 20:375-381. [PMID: 29736878 DOI: 10.1007/s40272-018-0295-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND The application of population pharmacokinetic models and Bayesian methods offers the potential to develop individualized therapeutic approaches. OBJECTIVES The current study presents an external evaluation of a vancomycin pharmacokinetic model in a pediatric cancer population and proposes an easy-to-use chart for clinicians for a priori vancomycin schedule adaptation to achieve target concentration. METHODS External evaluation of a population pharmacokinetic model of vancomycin administered via continuous infusion was realized in a new retrospective dataset of pediatric patients with cancer. The published population pharmacokinetic model was implemented in NONMEM 7.3 with the structural and variance parameter values set equal to estimates previously reported. Predictive performance was assessed by quantifying bias and accuracy of model prediction. Normalized prediction distribution errors were also evaluated. Dosage simulations were performed according to the target concentration. RESULTS A total of 77 patients were included in this study, representing 146 vancomycin courses and 289 concentrations. The model adequately predicted vancomycin concentrations (median prediction error % of - 9.4%, median |PE|% of 24.1%). Based on simulation results, vancomycin dosage (mg/kg) should be adapted for each child on the basis of body weight and cyclosporine coadministration. CONCLUSION The model previously proposed by Guilhaumou et al. in pediatric patients with solid or hematological malignant disease was externally validated. Simulations have enabled the description of new dosage schedules and creation of a chart to help clinicians adapt vancomycin dosage.
Collapse
Affiliation(s)
- Amélie Marsot
- Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France.
- Aix Marseille Université, Pharmacologie Intégrée Interface Clinique et Industriel, Institut des Neurosciences Timone-CNRS 7289, 13385, Marseille, France.
| | - F Gallais
- Aix Marseille Université, Pharmacologie Intégrée Interface Clinique et Industriel, Institut des Neurosciences Timone-CNRS 7289, 13385, Marseille, France
| | - C Galambrun
- Service d'Hématologie et Oncologie Pédiatrique, Hôpital de la Timone, Marseille, France
| | - C Coze
- Service d'Hématologie et Oncologie Pédiatrique, Hôpital de la Timone, Marseille, France
| | - O Blin
- Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
- Aix Marseille Université, Pharmacologie Intégrée Interface Clinique et Industriel, Institut des Neurosciences Timone-CNRS 7289, 13385, Marseille, France
| | - N Andre
- Service d'Hématologie et Oncologie Pédiatrique, Hôpital de la Timone, Marseille, France
- INSERM, UMR 911, Centre de Recherche en Oncologie biologique et en Oncopharmacologie, Aix-Marseille University, Marseille, France
| | - R Guilhaumou
- Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital de la Timone, 264 rue Saint Pierre, 13385, Marseille Cedex 5, France
- Aix Marseille Université, Pharmacologie Intégrée Interface Clinique et Industriel, Institut des Neurosciences Timone-CNRS 7289, 13385, Marseille, France
| |
Collapse
|
11
|
Riff C, Diaz A, Blin O, Leone M, Guilhaumou R, Bourgoin A. Tumescent local anaesthesia for breast cancer surgery in elderly women: about 6 cases. Anaesth Crit Care Pain Med 2018; 38:387-389. [PMID: 29864551 DOI: 10.1016/j.accpm.2018.05.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 05/07/2018] [Accepted: 05/07/2018] [Indexed: 10/14/2022]
Affiliation(s)
- C Riff
- Department of clinical pharmacology et Pharmacovigilance, AP-HM, 13385 Marseille, France; Integrated pharmacology and industrial clinical platform, Institut des Neurosciences Timone-AMU-CNRS 7289, Aix-Marseille Université, 13385 Marseille, France.
| | - A Diaz
- Department of anaesthesia and intensive care, Aix Marseille University, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, APHM, 13015 Marseille, France
| | - O Blin
- Department of clinical pharmacology et Pharmacovigilance, AP-HM, 13385 Marseille, France; Integrated pharmacology and industrial clinical platform, Institut des Neurosciences Timone-AMU-CNRS 7289, Aix-Marseille Université, 13385 Marseille, France
| | - M Leone
- Department of anaesthesia and intensive care, Aix Marseille University, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, APHM, 13015 Marseille, France
| | - R Guilhaumou
- Department of clinical pharmacology et Pharmacovigilance, AP-HM, 13385 Marseille, France
| | - A Bourgoin
- Department of anaesthesia and intensive care, Aix Marseille University, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, APHM, 13015 Marseille, France
| |
Collapse
|
12
|
Satori D, Setti J, Marsot A, Triglia T, Bruder N, Blin O, Velly L, Guilhaumou R. Suivi thérapeutique pharmacologique des beta-lactamines administrées en perfusion continue en réanimation. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O. Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. J Pharmacol Toxicol Methods 2017; 85:49-54. [DOI: 10.1016/j.vascn.2017.02.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 02/01/2017] [Accepted: 02/02/2017] [Indexed: 12/28/2022]
|
14
|
Kheloufi F, Default A, Rouby F, Laugier-Castellan D, Boyer M, Rodrigues B, Ponte-Astoul J, Jean-Pastor MJ, Blin O, Micallef J. Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre? Eur J Clin Pharmacol 2017; 73:1009-1018. [PMID: 28391408 DOI: 10.1007/s00228-017-2254-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 04/04/2017] [Indexed: 10/19/2022]
Abstract
PURPOSE Little is known about the informativeness of initial patient reports before they are reviewed by a pharmacovigilance centre (PVC). We aim to describe the patterns of patient adverse drug reaction (ADR) reporting in France and estimate the contribution of a review by a PVC assessor on the informativeness of these reports. METHODS A retrospective study was conducted on patient reports between July 2011 and July 2015. Informativeness of 16 key elements of information (including drug start and end date, duration of treatment, time to onset and duration of the ADR, outcome, medical history and concomitant medication) was assessed in initial reports before and after review by a pharmacovigilance assessor. RESULTS Overall, 240 reports concerning 522 ADR and involving 278 drugs were reported over this 4-year period. Mean number of available key elements of information in initial reports was increased from 11/16 to 15/16 after review of reports by the PVC. Time to onset and duration of the ADR were respectively available in only 51 and 58% of the reports before review compared to 83 and 90% after review. Medical history and concomitant medication were missing in 75% of the initial reports compared to less than 30% of the reports after review. Contacting the reporter enabled an increase of informativeness of most elements of information for more than 90% of the reports. CONCLUSION Patient reports often need to be completed on key elements of information that are required to assess reports. Both upstream education of patients and downstream intervention of a pharmacovigilance assessor to complete missing information could help to enhance the informativeness of such reports.
Collapse
Affiliation(s)
- F Kheloufi
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
- Aix Marseille Université, Institut de Neurosciences Timone, CNRS, 7289, Marseille, France
| | - A Default
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
- Aix Marseille Université, Institut de Neurosciences Timone, CNRS, 7289, Marseille, France
| | - F Rouby
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
- Aix Marseille Université, Institut de Neurosciences Timone, CNRS, 7289, Marseille, France
| | - D Laugier-Castellan
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
| | - M Boyer
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
| | - B Rodrigues
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
| | - J Ponte-Astoul
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
| | - M J Jean-Pastor
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
| | - O Blin
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France
- Aix Marseille Université, Institut de Neurosciences Timone, CNRS, 7289, Marseille, France
| | - J Micallef
- Regional Pharmacovigilance Centre of Marseille Provence Corse, Department of Clinical Pharmacology and Pharmacovigilance, Assistance Publique - Hôpitaux de Marseille, 270 boulevard Sainte Marguerite, 13009, Marseille, France.
- Aix Marseille Université, Institut de Neurosciences Timone, CNRS, 7289, Marseille, France.
| |
Collapse
|
15
|
Fakra E, Azorin JM, Belzeaux R, Adida M, Blin O, Kaladjian A. [Evaluating the efficacy of long acting injectable antipsychotics through clinical trials]. Encephale 2017; 42:S43-S46. [PMID: 28236992 DOI: 10.1016/s0013-7006(17)30053-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
After reminding the various phases of the development of molecules, this article will state the stages of commercialisation of treatments, underlining the FDA (Food and Drug Administration) and the EMA (European Medicine Agency) requirements. Like all the other treatments available in Europe and in the United States, the long acting injectable antipsychotics (LAI) have to prove their efficacy compared to placebo and their non-inferiority compared to a treatment of reference, usually the same molecule in the oral form. These criteria of efficacy have evolved over time. If initially classical criteria of symptomatic intensity (score on scale PANSS) were considered, criteria more adequate from a clinical perspective, such as relapse, but also related to functioning, quality of life and, more recently, costs-effectiveness have appeared. This evolution is probably due to several factors: vision on mental illness, progress in patient's rights and aspirations, but also the pregnant place of health costs recently taken in the evaluation of treatments. These modifications are also based on the indications of L.A.I., i.e. stabilized patients for whom the challenge is rehabilitation care more than the control of symptoms.
Collapse
Affiliation(s)
- E Fakra
- Service de Psychiatrie Adultes, CHU Saint-Etienne, 5 Chemin de la Marendière, 42055 Saint-Étienne Cedex 2, France.
| | - J-M Azorin
- SHU Psychiatrie Adultes, Hôpital Ste Marguerite, 13274 Marseille Cedex 9, France
| | - R Belzeaux
- SHU Psychiatrie Adultes, Hôpital Ste Marguerite, 13274 Marseille Cedex 9, France
| | - M Adida
- SHU Psychiatrie Adultes, Hôpital Ste Marguerite, 13274 Marseille Cedex 9, France
| | - O Blin
- Centre de Pharmacologie Clinique et Evaluation Thérapeutiques (APHM), UHC « La Timone », 28 bd Bd Jean Moulin, 13385 Marseille, France
| | - A Kaladjian
- Pôle de Psychiatrie des Adultes, CHU Robert Debré, Avenue du Général Koenig, 51092 Reims Cedex, France
| |
Collapse
|
16
|
Marsot A, Boucherie Q, Kheloufi F, Riff C, Braunstein D, Dupouey J, Guilhaumou R, Zendjidjian X, Bonin-Guillaume S, Fakra E, Guye M, Jirsa V, Azorin JM, Belzeaux R, Adida M, Micallef J, Blin O. [What can we expect from clinical trials in psychiatry?]. Encephale 2017; 42:S2-S6. [PMID: 28236988 DOI: 10.1016/s0013-7006(17)30046-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Clinical trials in psychiatry allow to build the regulatory dossiers for market authorization but also to document the mechanism of action of new drugs, to build pharmacodynamics models, evaluate the treatment effects, propose prognosis, efficacy or tolerability biomarkers and altogether to assess the impact of drugs for patient, caregiver and society. However, clinical trials have shown some limitations. Number of recent dossiers failed to convince the regulators. The clinical and biological heterogeneity of psychiatric disorders, the pharmacokinetic and pharmacodynamics properties of the compounds, the lack of translatable biomarkers possibly explain these difficulties. Several breakthrough options are now available: quantitative system pharmacology analysis of drug effects variability, pharmacometry and pharmacoepidemiology, Big Data analysis, brain modelling. In addition to more classical approaches, these opportunities lead to a paradigm change for clinical trials in psychiatry.
Collapse
Affiliation(s)
- A Marsot
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - Q Boucherie
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - F Kheloufi
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - C Riff
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - D Braunstein
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - J Dupouey
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - R Guilhaumou
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - X Zendjidjian
- Service de Psychiatrie, Hôpital de la Conception, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - S Bonin-Guillaume
- Département de Gériatrie, Hôpital Sainte-Marguerite, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - E Fakra
- Service de Psychiatrie Adultes, CHU Saint-Étienne, 5 Chemin de la Marendière, 42055 Saint-Étienne cedex 2, France
| | - M Guye
- Aix-Marseille Université, CNRS, CRMBM UMR 7339, 13385 Marseille, France ; APHM, Hôpitaux de la Timone, Pôle d'imagerie Médicale, CEMEREM, 13005 Marseille, France
| | - V Jirsa
- Aix-Marseille Université, Institut de Neurosciences des Systèmes, 13385 Marseille, France ; INSERM, UMR_S 1106, 13385 Marseille, France
| | - J-M Azorin
- SHU Psychiatrie Adultes, Hôpital Sainte Marguerite, 13274 Marseille, France
| | - R Belzeaux
- SHU Psychiatrie Adultes, Hôpital Sainte Marguerite, 13274 Marseille, France
| | - M Adida
- SHU Psychiatrie Adultes, Hôpital Sainte Marguerite, 13274 Marseille, France
| | - J Micallef
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France
| | - O Blin
- Pharmacologie Clinique et Pharmacovigilance, AP-HM, Piici, UMR 7298, Aix-Marseille Université-CNRS, Marseille, France.
| |
Collapse
|
17
|
Albi A, Pasternak O, Minati L, Marizzoni M, Bartrés-Faz D, Bargalló N, Bosch B, Rossini PM, Marra C, Müller B, Fiedler U, Wiltfang J, Roccatagliata L, Picco A, Nobili FM, Blin O, Sein J, Ranjeva JP, Didic M, Bombois S, Lopes R, Bordet R, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Frisoni G, Jovicich J. Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. Hum Brain Mapp 2016; 38:12-26. [PMID: 27519630 DOI: 10.1002/hbm.23350] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 07/11/2016] [Accepted: 08/04/2016] [Indexed: 01/16/2023] Open
Abstract
Free water elimination (FWE) in brain diffusion MRI has been shown to improve tissue specificity in human white matter characterization both in health and in disease. Relative to the classical diffusion tensor imaging (DTI) model, FWE is also expected to increase sensitivity to microstructural changes in longitudinal studies. However, it is not clear if these two models differ in their test-retest reproducibility. This study compares a bi-tensor model for FWE with DTI by extending a previous longitudinal-reproducibility 3T multisite study (10 sites, 7 different scanner models) of 50 healthy elderly participants (55-80 years old) scanned in two sessions at least 1 week apart. We computed the reproducibility of commonly used DTI metrics (FA: fractional anisotropy, MD: mean diffusivity, RD: radial diffusivity, and AXD: axial diffusivity), derived either using a DTI model or a FWE model. The DTI metrics were evaluated over 48 white-matter regions of the JHU-ICBM-DTI-81 white-matter labels atlas, and reproducibility errors were assessed. We found that relative to the DTI model, FWE significantly reduced reproducibility errors in most areas tested. In particular, for the FA and MD metrics, there was an average reduction of approximately 1% in the reproducibility error. The reproducibility scores did not significantly differ across sites. This study shows that FWE improves sensitivity and is thus promising for clinical applications, with the potential to identify more subtle changes. The increased reproducibility allows for smaller sample size or shorter trials in studies evaluating biomarkers of disease progression or treatment effects. Hum Brain Mapp 38:12-26, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Angela Albi
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Ofer Pasternak
- Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ludovico Minati
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Moira Marizzoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni di Dio-FBF, Brescia, Italy
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain
| | - Núria Bargalló
- Department of Neuroradiology and Magnetic Resonance Image core Facility, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, and IDIBAPS, Barcelona, Spain
| | - Paolo Maria Rossini
- Department Geriatrics Neuroscience & Orthopedics, Catholic University, Policlinic Gemelli, Rome, Italy.,IRCSS S.Raffaele Pisana, Rome, Italy
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | - Bernhard Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jens Wiltfang
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg August University, Göttingen, Germany
| | - Luca Roccatagliata
- Department of Neuroradiology, IRCSS San Martino University Hospital and IST, Genoa, Italy.,Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Flavio Mariano Nobili
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Oliver Blin
- Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS, UMR, Marseille, 7289, France
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix Marseille Université-CNRS, Marseille, France
| | | | - Mira Didic
- APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France.,Aix Marseille Université, Inserm, INS UMR_S 1106, Marseille, 13005, France
| | - Stephanie Bombois
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Renaud Lopes
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Régis Bordet
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Hélène Gros-Dagnac
- INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France.,Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse Cedex 9, France
| | - Pierre Payoux
- INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France.,Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse Cedex 9, France
| | | | | | | | - Antonio Ferretti
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Massimo Caulo
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | | | | | - Andrea Soricelli
- IRCCS SDN, Naples, Italy.,University of Naples Parthenope, Naples, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | | | - Piero Floridi
- Neuroradiology Unit, Perugia General Hospital, Perugia, Italy
| | - Magda Tsolaki
- 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece.,Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Giovanni Frisoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni di Dio-FBF, Brescia, Italy.,Memory Clinic and LANVIE Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | | |
Collapse
|
18
|
Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. J Intern Med 2016; 279:576-91. [PMID: 26940242 DOI: 10.1111/joim.12482] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. OBJECTIVE To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog (also referred to as the European ADNI study). METHODS A total of 147 aMCI patients were enrolled in 13 European memory clinics. Patients underwent clinical and neuropsychological evaluation, magnetic resonance imaging (MRI), electroencephalography (EEG) and lumbar puncture to assess the levels of amyloid β peptide 1-42 (Aβ42), tau and p-tau, and blood samples were collected. Genetic (APOE), neuroimaging (3T morphometry and diffusion MRI) and EEG (with resting-state and auditory oddball event-related potential (AO-ERP) paradigm) biomarkers were evaluated. RESULTS Prodromal AD was found in 55 aMCI patients defined by low Aβ42 in the cerebrospinal fluid (Aβ positive). Compared to the aMCI group with high Aβ42 levels (Aβ negative), Aβ positive patients showed poorer visual (P = 0.001), spatial recognition (P < 0.0005) and working (P = 0.024) memory, as well as a higher frequency of APOE4 (P < 0.0005), lower hippocampal volume (P = 0.04), reduced thickness of the parietal cortex (P < 0.009) and structural connectivity of the corpus callosum (P < 0.05), higher amplitude of delta rhythms at rest (P = 0.03) and lower amplitude of posterior cingulate sources of AO-ERP (P = 0.03). CONCLUSION These results suggest that, in aMCI patients, prodromal AD is characterized by a distinctive cognitive profile and genetic, neuroimaging and neurophysiological biomarkers. Longitudinal assessment will help to identify the role of these biomarkers in AD progression.
Collapse
Affiliation(s)
- S Galluzzi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - M Marizzoni
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - C Babiloni
- Department of Physiology and Pharmacology, University of Rome 'La Sapienza', Rome, Italy.,IRCCS San Raffaele Pisana of Rome, Rome, Italy
| | - D Albani
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - L Antelmi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - C Bagnoli
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - D Bartres-Faz
- Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, University of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
| | - S Cordone
- Department of Physiology and Pharmacology, University of Rome 'La Sapienza', Rome, Italy
| | - M Didic
- Aix-Marseille Université, INSERM, Marseille, France.,Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
| | - L Farotti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - U Fiedler
- Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - G Forloni
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - N Girtler
- Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy
| | - T Hensch
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - J Jovicich
- Center for Mind/Brain Sciences, University of Trento, Trento, Italy
| | - A Leeuwis
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands
| | - C Marra
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy
| | - J L Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, and IDIBAPS, Barcelona, Catalunya, Spain
| | - F Nobili
- Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy
| | - J Pariente
- INSERM, Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France
| | - L Parnetti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - P Payoux
- INSERM, Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France
| | - C Del Percio
- SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy
| | - J-P Ranjeva
- Aix-Marseille Université, INSERM, Marseille, France.,Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
| | - E Rolandi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - P M Rossini
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy
| | - P Schönknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - A Soricelli
- SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy
| | - M Tsolaki
- Third Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - P J Visser
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands
| | - J Wiltfang
- Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany
| | - J C Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK
| | - R Bordet
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - O Blin
- Mediterranean Institute of Cognitive Neurosciences, Aix Marseille University, Marseille, France
| | - G B Frisoni
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy.,Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | | |
Collapse
|
19
|
Marchitelli R, Minati L, Marizzoni M, Bosch B, Bartrés-Faz D, Müller BW, Wiltfang J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Schönknecht P, Hensch T, Hoffmann KT, Kuijer JP, Visser PJ, Barkhof F, Frisoni GB, Jovicich J. Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Hum Brain Mapp 2016; 37:2114-32. [PMID: 26990928 DOI: 10.1002/hbm.23157] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 02/16/2016] [Accepted: 02/17/2016] [Indexed: 12/31/2022] Open
Abstract
Understanding how to reduce the influence of physiological noise in resting state fMRI data is important for the interpretation of functional brain connectivity. Limited data is currently available to assess the performance of physiological noise correction techniques, in particular when evaluating longitudinal changes in the default mode network (DMN) of healthy elderly participants. In this 3T harmonized multisite fMRI study, we investigated how different retrospective physiological noise correction (rPNC) methods influence the within-site test-retest reliability and the across-site reproducibility consistency of DMN-derived measurements across 13 MRI sites. Elderly participants were scanned twice at least a week apart (five participants per site). The rPNC methods were: none (NPC), Tissue-based regression, PESTICA and FSL-FIX. The DMN at the single subject level was robustly identified using ICA methods in all rPNC conditions. The methods significantly affected the mean z-scores and, albeit less markedly, the cluster-size in the DMN; in particular, FSL-FIX tended to increase the DMN z-scores compared to others. Within-site test-retest reliability was consistent across sites, with no differences across rPNC methods. The absolute percent errors were in the range of 5-11% for DMN z-scores and cluster-size reliability. DMN pattern overlap was in the range 60-65%. In particular, no rPNC method showed a significant reliability improvement relative to NPC. However, FSL-FIX and Tissue-based physiological correction methods showed both similar and significant improvements of reproducibility consistency across the consortium (ICC = 0.67) for the DMN z-scores relative to NPC. Overall these findings support the use of rPNC methods like tissue-based or FSL-FIX to characterize multisite longitudinal changes of intrinsic functional connectivity. Hum Brain Mapp 37:2114-2132, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Rocco Marchitelli
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Ludovico Minati
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy.,Scientific Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Moira Marizzoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni Di Dio-FBF, Brescia, Italy
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, and IDIBAPS, Barcelona, Spain
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat De Barcelona and IDIBAPS, Barcelona, Spain
| | - Bernhard W Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jens Wiltfang
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg August University, Göttingen, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Luca Roccatagliata
- Department of Neuroradiology, IRCSS San Martino University Hospital and IST, Genoa, Italy.,Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Flavio Nobili
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Oliver Blin
- Pharmacology, Assistance Publique - Hôpitaux De Marseille, Aix-Marseille University-CNRS, UMR, Marseille, 7289, France
| | - Stephanie Bombois
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Renaud Lopes
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Régis Bordet
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix Marseille Université-CNRS, Marseille, France
| | | | - Mira Didic
- APHM, CHU Timone, Service De Neurologie Et Neuropsychologie, Marseille, France.,Aix-Marseille Université, INSERM INS UMR_S 1106, Marseille, 13005, France
| | - Hélène Gros-Dagnac
- INSERM, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, Toulouse, France.,Université De Toulouse, UPS, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, CHU Purpan, Place Du Dr Baylac, Toulouse Cedex 9, France
| | - Pierre Payoux
- INSERM, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, Toulouse, France.,Université De Toulouse, UPS, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, CHU Purpan, Place Du Dr Baylac, Toulouse Cedex 9, France
| | | | | | | | - Núria Bargalló
- Department of Neuroradiology and Magnetic Resonace Image Core Facility, Hospital Clínic De Barcelona, IDIBAPS, Barcelona, Spain
| | - Antonio Ferretti
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Massimo Caulo
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | | | | | - Andrea Soricelli
- IRCCS SDN, Naples, Italy.,University of Naples Parthenope, Naples, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | | | - Piero Floridi
- Perugia General Hospital, Neuroradiology Unit, Perugia, Italy
| | - Magda Tsolaki
- 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece.,Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Paolo Maria Rossini
- Department of Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy.,IRCSS S.Raffaele Pisana, Rome, Italy
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | - Peter Schönknecht
- Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany
| | - Tilman Hensch
- Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany
| | | | - Joost P Kuijer
- Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, the Netherlands
| | - Pieter Jelle Visser
- Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.,Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands
| | - Frederik Barkhof
- Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands
| | - Giovanni B Frisoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni Di Dio-FBF, Brescia, Italy.,Memory Clinic and LANVIE, Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| |
Collapse
|
20
|
Cordone S, Del Percio C, Marzano N, Noce G, Bagnoli C, Rossini P, Soricelli A, Famá F, Bartres Faz D, Blin O, Payoux P, Bordet R, Müller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukart J, Bertolino A, Forloni G, Richardson J, Frisoni G, Babiloni C. ID 286 – Auditory oddball event-related potentials cortical sources are related to cerebrospinal fluid (CSF)® amyloid (A®) level in amnesic MCI subjects. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Noce G, Del Percio C, Marzano N, Cordone S, Bagnoli C, Rossini P, Soricelli A, Nobili F, Bartres Faz D, Blin O, Payoux P, Bordet R, Müller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukar J, Bertolino A, Forloni G, Richardson J, Frisoni G, Babiloni C. ID 284 – Abnormal delta cortical sources of resting state eyes closed EEG rhythms correlate with cerebrospinal fluid (CSF) ® amyloid (A®) level in amnesic MCI subjects. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Babiloni C, Del Percio C, Marzano N, Cordone S, Noce G, Bagnoli C, Rossini PM, Soricelli A, Nobili FM, Faz DB, Blin O, Payoux P, Bordet R, Mueller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukart J, Bertolino A, Forloni G, Frasca A, Richardson J, Bastlund JF, Clausen B, Bentivoglio M, Fabene P, Bertini G, Dix S, Kelley J, Drinkenburg W, Frisoni G. Cortical generation of on-going “Delta” and “Alpha” EEG rhythms in mouse models of Alzheimer’s disease and Alzheimer’s disease patients at prodromic stages. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.082] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
23
|
Cancel A, Comte M, Truillet R, Boukezzi S, Rousseau PF, Zendjidjian XY, Sage T, Lazerges PE, Guedj E, Khalfa S, Azorin JM, Blin O, Fakra E. Childhood neglect predicts disorganization in schizophrenia through grey matter decrease in dorsolateral prefrontal cortex. Acta Psychiatr Scand 2015; 132:244-56. [PMID: 26038817 DOI: 10.1111/acps.12455] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/15/2015] [Indexed: 12/11/2022]
Abstract
OBJECTIVE Psychosocial trauma during childhood is associated with schizophrenia vulnerability. The pattern of grey matter decrease is similar to brain alterations seen in schizophrenia. Our objective was to explore the links between childhood trauma, brain morphology and schizophrenia symptoms. METHOD Twenty-one patients with schizophrenia stabilized with atypical antipsychotic monotherapy and 30 healthy control subjects completed the study. Anatomical MRI images were analysed using optimized voxel-based morphometry (VBM). Childhood trauma was assessed with the Childhood Trauma Questionnaire, and symptoms were rated on the Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) (disorganization, positive and negative symptoms). In the schizophrenia group, we used structural equation modelling in a path analysis. RESULTS Total grey matter volume was negatively associated with emotional neglect (EN) in patients with schizophrenia. Whole-brain VBM analyses of grey matter in the schizophrenia group revealed a specific inversed association between EN and the right dorsolateral prefrontal cortex (DLPFC). Path analyses identified a well-fitted model in which EN predicted grey matter density in DLPFC, which in turn predicted the disorganization score. CONCLUSION Our findings suggest that EN during childhood could have an impact on psychopathology in schizophrenia, which would be mediated by developmental effects on brain regions such as the DLPFC.
Collapse
Affiliation(s)
- A Cancel
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - M Comte
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France
| | - R Truillet
- Public Assistance for Marseille Hospitals (APHM) Unit for Clinical Pharmacology and Therapeutic Evaluation (CIC-UPCET), CHU Timone Hospital, Marseille, France
| | - S Boukezzi
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France
| | - P-F Rousseau
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Psychiatry Unit, Saint Anne Military Training Hospital, Toulon, France
| | - X Y Zendjidjian
- Department of Psychiatry, La Conception University Hospital, Marseille, France
| | - T Sage
- Clinic of Mental Health, L'escale, Orpea-Clinéa, Saint-Victoret, France
| | - P-E Lazerges
- Department of Psychiatry, Sainte Marguerite University Hospital, Marseille, France
| | - E Guedj
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Biophysics and Nuclear Medicine Department, Timone Hospital, Marseille, France
| | - S Khalfa
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France
| | - J-M Azorin
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Department of Psychiatry, Sainte Marguerite University Hospital, Marseille, France
| | - O Blin
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Public Assistance for Marseille Hospitals (APHM) Unit for Clinical Pharmacology and Therapeutic Evaluation (CIC-UPCET), CHU Timone Hospital, Marseille, France
| | - E Fakra
- Timone Institute of Neuroscience, UMR 7289, CNRS and Aix-Marseille University, Marseille, France.,Department of Psychiatry, University Hospital of Saint-Etienne, Saint-Etienne, France
| |
Collapse
|
24
|
Boucherie Q, Gentile G, Sciortino V, Blin O, Micallef J, Bonin-Guillaume S. P-397: Four-year prescription trends of profile of antipsychotics use in patients with dementia. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30494-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Salgado-Pineda P, Landin-Romero R, Fakra E, Delaveau P, Amann BL, Blin O. Structural abnormalities in schizophrenia: further evidence on the key role of the anterior cingulate cortex. Neuropsychobiology 2015; 69:52-8. [PMID: 24457222 DOI: 10.1159/000356972] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Accepted: 11/02/2013] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The present study examined whole-brain structural abnormalities in schizophrenia, with a special focus on the anterior and posterior cingulate cortex (ACC, PCC) as this is an understudied issue in schizophrenia. METHOD Whole-brain voxel-based morphometry analyses of gray matter (GM) and white matter (WM) were performed to detect volumetric differences between 14 patients with schizophrenia and 14 healthy controls matched for age, sex, educational level and parents' educational level. We examined within-group GM and WM correlations and completed the analysis with measurements of sulci in medial cortical areas. RESULTS Compared with the healthy controls, the schizophrenic patients showed significant decreases in GM volumes in the ACC and PCC, and in neighboring WM regions such as the corpus callosum and the fimbriae of the fornix. Moreover, the patient group also displayed a negative correlation between volumes of GM and WM in the ACC. Finally, the patients showed significantly reduced volumes in the right cingulate sulci and left inferior frontal sulci. CONCLUSION Our results replicate typical brain-structural abnormalities with new findings in the medial prefrontal cortex, suggested to be a key region in this disorder.
Collapse
Affiliation(s)
- P Salgado-Pineda
- FIDMAG Hermanas Hospitalarias Research Foundation, Sant Boi de Llobregat and CIBERSAM, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
26
|
Jovicich J, Marizzoni M, Bosch B, Bartrés-Faz D, Arnold J, Benninghoff J, Wiltfang J, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Chanoine V, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Ragucci M, Soricelli A, Salvadori N, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Otto J, Reiss-Zimmermann M, Hoffmann KT, Galluzzi S, Frisoni GB. Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. Neuroimage 2014; 101:390-403. [DOI: 10.1016/j.neuroimage.2014.06.075] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 04/30/2014] [Accepted: 06/28/2014] [Indexed: 12/13/2022] Open
|
27
|
Babiloni C, Del Percio C, Marzano N, Noce G, Cordone S, Bagnoli C, Rossini PM, Soricelli A, Nobili F, Bartrés‐Faz D, Blin O, Payoux P, Bordet R, Mueller B, Tsolaki M, Parnetti L, Hegerl U, Hensch T, Dukar J, Bertolino A, Forloni G, Richardson J, Frisoni G. P1‐216: FRONTAL CORTICAL SOURCES OF AUDITORY ODDBALL EVENT‐RELATED POTENTIALS ARE RELATED TO CEREBROSPINAL FLUID β AMYLOID IN AMNESTIC MCI SUBJECTS. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.05.455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | | | | | | | | | | | | | - Andrea Soricelli
- Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | - Flavio Nobili
- Clinical Neurophysiology, Department of Neursciences, Ophthalmology and GeneticsUniversity of GenoaGenoaItaly
| | | | - Oliver Blin
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Université de la MéditerranéeMarseilleFrance
| | - Pierre Payoux
- Institut National de la Santè et de la Recherche MédicaleToulouseFrance
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Deguil J, Ravasi L, Auffret A, Babiloni C, Bartres Faz D, Bragulat V, Cassé-Perrot C, Colavito V, Herrero Ezquerro MT, Lamberty Y, Lanteaume L, Pemberton D, Pifferi F, Richardson JC, Schenker E, Blin O, Tarragon E, Bordet R. Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans. Drug Discov Today Technol 2014; 10:e329-42. [PMID: 24179995 DOI: 10.1016/j.ddtec.2013.03.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
In chronic diseases such as Alzheimer's disease (AD), the arsenal of biomarkers available to determine the effectiveness of symptomatic treatment is very limited. Interpretation of the results provided in literature is cumbersome and it becomes difficult to predict their standardization to a larger patient population. Indeed, cognitive assessment alone does not appear to have sufficient predictive value of drug efficacy in early clinical development of AD treatment. In recent years, research has contributed to the emergence of new tools to assess brain activity relying on innovative technologies of imaging and electrophysiology. However, the relevance of the use of these newer markers in treatment response assessment is waiting for validation. This review shows how the early clinical assessment of symptomatic drugs could benefit from the inclusion of suitable pharmacodynamic markers. This review also emphasizes the importance of re-evaluating a step-by-step strategy in drug development.
Collapse
|
29
|
Jovicich J, Marizzoni M, Sala‐Llonch R, Bosch B, Bartrés‐Faz D, Arnold J, Benninghoff J, Wiltfang J, Roccatagliata L, Nobili F, Hensch T, Tränkner A, Schönknecht P, Leroy M, Bordet R, Chanoine V, Ranjeva J, Didic M, Gros‐Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargallo N, Blin O, Frisoni G. P3–121: Test‐retest reproducibility of brain morphometry, diffusion and resting‐state fMRI: A 3T consortium study. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | - Moira Marizzoni
- Lenitem Laboratory of Epidemiology, Neuroimaging & Telemedicine ‐ IRCCS San Giovanni di Dio‐FBF Brescia Italy
| | | | | | | | | | | | | | - Luca Roccatagliata
- Department of Neuroscience Ophthalmology and Genetics, University of Genoa Genoa Italy
| | - Flavio Nobili
- Clinical Neurophysiology, Department of Neursciences Ophthalmology and Genetics, University of Genoa Genoa Italy
| | - Tilman Hensch
- University of Leipzig Department of Psychiatry and Department of Neuroradiology Leipzig Germany
| | | | | | | | | | - Valérie Chanoine
- CIC‐UPCET, Chu La Timone, AP‐HM, UMR CNRS‐Université de la Méditerranée Marseille France
| | - Jean‐Philippe Ranjeva
- CIC‐UPCET, Chu La Timone, AP‐HM, UMR CNRS‐Université de la Méditerranée Marseille France
| | - Mira Didic
- Service de Neurologie et Neuropsychologie Marseille France
| | | | - Pierre Payoux
- Institut National de la Santè et de la Recherche Médicale Toulouse France
| | | | | | | | | | - Oliver Blin
- CIC‐UPCET, Chu La Timone, AP‐HM, UMR CNRS‐Université de la Méditerranée Marseille France
| | | |
Collapse
|
30
|
Pifferi F, Rahman A, Languille S, Auffret A, Babiloni C, Blin O, Lamberty Y, Richardson JC, Aujard F. Effects of dietary resveratrol on the sleep-wake cycle in the non-human primate gray mouse lemur (Microcebus murinus). Chronobiol Int 2012; 29:261-70. [PMID: 22390239 DOI: 10.3109/07420528.2011.654019] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Converging evidence shows that the non-human primate gray mouse lemur (Microcebus murinus) is ideal for the study of the aging process and for testing the effects of new therapies and dietary interventions on age-associated pathologies. One such dietary supplement is resveratrol (RSV), a dietary polyphenolic compound with several positive effects on metabolic functions and longevity. However, little is known about the effect of RSV on the lemur sleep-wake cycle, which reflects mammalian brain function and health. In the present study, the authors investigated this effect by comparing sleep-wake cycles in adult lemurs based on electroencephalographic (EEG) rhythms. The effect of short-term RSV supplementation on the sleep-wake cycle of mouse lemurs was evaluated in entrained conditions (long-day photoperiods, light:dark 14:10). After 3 wks of RSV supplementation, the animals exhibited a significantly increased proportion of active-wake time, occurring mainly during the resting phase of the sleep-wake cycle (+163%). The increase in active-wake time with RSV supplementation was accompanied by a significant reduction of both paradoxical sleep (-95%) and slow-wave sleep (-38%). These changes mainly occurred during the resting phase of the sleep-wake cycle (RSV supplementation induced negligible changes in active-wake time during the active phase of the sleep-wake cycle). The present data suggest that RSV may be a potent regulator of sleep-wake rhythms and could be of major interest in the study of sleep perturbations associated with aging and neuropathology.
Collapse
|
31
|
Jovicich J, Borsci G, Marizzoni M, Sala‐Llonch R, Bargallò N, Bartrés‐Faz D, Benninghoff J, Wiltfang J, Roccatagliata L, Nobili F, Hoffmann K, Günther T, Schönknecht P, Monnet A, Bordet R, Chanoine V, Auffret A, Ranjeva J, Blin O, Gros‐Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Hardemark H, Frisoni G. P2‐235: Pharmacog: Multi‐site MRI calibration to study progression of Alzheimer's disease. Alzheimers Dement 2012. [DOI: 10.1016/j.jalz.2012.05.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
| | - Genoveffa Borsci
- LENITEM Laboratory of EpidemiologyNeuroimaging, & Telemedicine ‐ IRCCS San Giovanni di Dio‐FBFBresciaItaly
| | - Moira Marizzoni
- Laboratory of Epidemiology and NeuroimagingIRCCS FatebenefratelliBresciaItaly
| | | | | | | | - Jens Benninghoff
- Universitaet Duisburg‐Essen Department of Psychiatry and Nuclear MedicineEssenGermany
| | - Jens Wiltfang
- Universitaet Duisburg‐Essen Department of Psychiatry and Nuclear MedicineEssemGermany
| | - Luca Roccatagliata
- Department of NeuroscienceOphthalmology and Genetics University of GenoaGenoaItaly
| | - Flavio Nobili
- Clinical NeurophysiologyDepartment of NeurosciencesOphthalmology and GeneticsUniversity of GenoaGenoaItaly
| | - Karl‐Titus Hoffmann
- University Hospital LeipzigDepartment of PsychiatrySection of NeuroradiologyLeipzigGermany
| | - Thomas Günther
- University Hospital LeipzigDepartment of PsychiatrySection of NeuroradiologyLeipzigGermany
| | - Peter Schönknecht
- University Hospital LeipzigDepartment of PsychiatrySection of NeuroradiologyLeipzigGermany
| | | | | | - Valérie Chanoine
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Université de la MéditerranéeMarseilleFrance
| | - Alexandra Auffret
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Université de la MéditerranéeMarseilleFrance
| | - Jean‐Philippe Ranjeva
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Université de la MéditerranéeMarseilleFrance
| | - Oliver Blin
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Université de la MéditerranéeMarseilleFrance
| | | | - Pierre Payoux
- Institut National de la Santè et de la Recherche MédicaleToulouseFrance
| | | | | | | | | | | |
Collapse
|
32
|
Languille S, Blanc S, Blin O, Canale CI, Dal-Pan A, Devau G, Dhenain M, Dorieux O, Epelbaum J, Gomez D, Hardy I, Henry PY, Irving EA, Marchal J, Mestre-Francés N, Perret M, Picq JL, Pifferi F, Rahman A, Schenker E, Terrien J, Théry M, Verdier JM, Aujard F. The grey mouse lemur: a non-human primate model for ageing studies. Ageing Res Rev 2012; 11:150-62. [PMID: 21802530 DOI: 10.1016/j.arr.2011.07.001] [Citation(s) in RCA: 128] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Revised: 07/04/2011] [Accepted: 07/08/2011] [Indexed: 01/27/2023]
Abstract
The use of non-human primate models is required to understand the ageing process and evaluate new therapies against age-associated pathologies. The present article summarizes all the contributions of the grey mouse lemur Microcebus murinus, a small nocturnal prosimian primate, to the understanding of the mechanisms of ageing. Results from studies of both healthy and pathological ageing research on the grey mouse lemur demonstrated that this animal is a unique model to study age-dependent changes in endocrine systems, biological rhythms, thermoregulation, sensorial, cerebral and cognitive functions.
Collapse
|
33
|
Bouloudnine S, Azorin JM, Petitjean F, Parry-Pousse P, Sciorato F, Blin O, Fakra E. Analyse de discours de patients schizophrènes et perception des effets indésirables de différents antipsychotiques atypiques. Étude TALK. Encephale 2011; 37 Suppl 2:S143-50. [DOI: 10.1016/s0013-7006(11)70042-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Abstract
In spite of the frequency of sexual dysfunction in schizophrenic patients and antipsychotic-treated schizophrenic patients, few studies have been performed. The relationship of schizophrenia to sexual pathology is variable and complex, and of course different between men and women. Few evaluation methods have been proposed or validated. Antipsychotics may improve some aspects of sexual behaviour in schizophrenic patients. However, sexual dysfunction is also a possible side effect of these drugs. The evaluation of antipsychotics is often restricted to prolactin measurement, the relationship with sexual disorders of which has not been fully established. Preliminary data suggest that the capacity to induce sexual disorders differs from one antipsychotic to another. The available data on the mechanisms of sexual dysfunction, the pharmacological profile and the sexual effects of classical neuroleptics (haloperidol and thioridazine) and second generation antipsychotics available in France (amisulpride, clozapine, risperidone, olanzapine) are reviewed.
Collapse
Affiliation(s)
- S Tardieu
- Cellule d'Evaluation Médicale, Santé Publique, Assistance Publique-Hôpitaux de Marseille, 80, rue Brochier, 13354 Marseille cedex 05, France
| | | | | | | | | | | |
Collapse
|
35
|
Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. Motor activation in multiple system atrophy and Parkinson disease: A PET study. Neurology 2010; 75:1174-80. [DOI: 10.1212/wnl.0b013e3181f4d78f] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging 2010; 31:1443-51, 1451.e1. [PMID: 20541287 DOI: 10.1016/j.neurobiolaging.2010.04.036] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2010] [Revised: 04/29/2010] [Accepted: 04/29/2010] [Indexed: 11/25/2022]
Abstract
Clinical trials of disease modifying drugs for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) might benefit from enrichment with true AD cases. Four hundred five MCI patients (143 converters and 262 nonconverters to AD within 2 years) of the Alzheimer's disease Neuroimaging Initiative (ADNI) were used. Markers for enrichment were hippocampal atrophy on magnetic resonance (MRI), temporoparietal hypometabolism on FDG PET, cerebrospinal fluid (CSF) biomarkers (Abeta42, tau, and phospho-tau), and cortical amyloid deposition (11C-PIB positron emission tomography (PET)). Two separate enrichment strategies were tested to A) maximize the proportion of MCI converters screened in, and B) minimize the proportion of MCI converters screened out. Based on strategy A, when compared with no enrichment and ADAS-Cog as an outcome measure (sample size of 834), enrichment with 18F-FDG PET and hippocampal volume lowered samples size to 260 and 277 cases per arm, but at the cost of screening out 1,597 and 434 cases per arm. When compared with no enrichment and clinical dementia rating (CDR-SOB) as an outcome measure (sample size of 674), enrichment with hippocampal volume and Abeta42 lowered sample sizes to 191 and 291 cases per arm, with 639 and 157 screened out cases. Strategy B reduced the number of screened out cases (740 for [11C]-PIB PET, 101 hippocampal volume, 82 ADAS-COG and 330 for [18F]-FDG PET) but at the expense of decreased power and a relative increase size (740 for [11C]-PIB PET, 676 for hippocampal volume, 744 for ADAS-Cog, and 517 for [18F]-FDG PET). Enrichment comes at the price of an often relevant proportion of screened out cases, and in clinical trial settings, the balance between enrichment of screened in and loss of screened out patients should be critically discussed.
Collapse
Affiliation(s)
- M Lorenzi
- LENITEM Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio-FBF, Brescia, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Kilani M, Micallef J, Soubrouillard C, Rey-Lardiller D, Dematteï C, Dib M, Philippot P, Ceccaldi M, Pouget J, Blin O. A longitudinal study of the evolution of cognitive function and affective state in patients with amyotrophic lateral sclerosis. ACTA ACUST UNITED AC 2009; 5:46-54. [PMID: 15204024 DOI: 10.1080/14660820310017560] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVES The study aimed to evaluate cognitive function and emotional reactivity in 18 patients with ALS, compared to 19 matched controls, and assess their evolution over a 12-month period. METHODS 18 ALS patients and 19 matched controls were included, and assessed at inclusion, six months and twelve months later. Depression was evaluated with the Geriatric Depression Scale, and cognitive function with the Folstein Mini Mental State. A battery of psychometric tests (Wisconsin Card Sorting Test (WCST), the numerical Empan test, the Trail-making test, the Boston Naming Test, the 15-word Rey memory test, the Benton visual retention test and the Raven Progressive Matrix) was used to measure frontal processing and non-frontal function. Emotional reactivity was measured with the film-evoked emotions test. RESULTS ALS patients were significantly more depressed than controls, as measured on the Geriatric Depression Scale, and depression increased over the study period. There was a very mild defect in cognitive function, and a performance deficit in the Trail-making test, a measure of frontal processing. These deficits, unlike neuromuscular function and depression, did not aggravate over the 12 months of the study. There was no observable change in non-frontal function. Emotional reactivity did not differ significantly between ALS patients and controls. CONCLUSIONS This study provides further evidence for a mild defect in frontal cognitive processing in ALS patients that evolves only slowly, if at all, with time.
Collapse
Affiliation(s)
- M Kilani
- CPCET et Pharmacologie Clinique, Institut de Neurosciences, Physiologiques et Cognitives, Faculte de Medecine, FRE 2109 CNRS-Universite de la Mediterranee, Assistance Publique-Hopitaux de Marseille-Hopital de la Timone, 13385 Marseille Cedex 5, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Micallef J, Rey M, Eusebio A, Audebert C, Rouby F, Jouve E, Tardieu S, Blin O. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009; 67:333-40. [PMID: 19220275 PMCID: PMC2675044 DOI: 10.1111/j.1365-2125.2008.03310.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2008] [Indexed: 01/01/2023] Open
Abstract
AIMS To assess the sleepiness induced by pramipexole, a D2/D3-dopamine receptor agonist commonly used in Parkinson's disease and restless legs syndrome, without the problem of the confounding factors related to the disease. METHODS Placebo, bromocriptine (2.5 mg), L-dopa (100 mg) and pramipexole (0.5 mg) were administered in a single oral dose on four separate days, with at least a 2-week wash-out period in a randomized cross-over design. Induced somnolence was assessed using Multiple Sleep Latency Test (MSLT) and subjective scaling of vigilance. Twelve male subjects (26.3 +/- 5.5 years old) without anxiety, mood, sleep or sedation disorders were enrolled. RESULTS Pramipexole significantly reduced mean sleep latency compared with placebo 3 h 30 min [-6.1 min (-9.8, -2.4), P = 0.002] and 5 h 30 min [-5.6 min (-7.7, -3.5), P = 0.003] after administration. In addition, the total duration of sleep during the tests was higher with pramipexole than with placebo [+6.0 min (2.3, 9.7), P < 0.001]. These differences were not observed with L-dopa and bromocriptine in comparison with placebo. The induced sleepiness was not associated with an increase in subjective somnolence scaling, indicating that this adverse event may occur without prior warning. CONCLUSIONS These results show that a single oral dose of pramipexole induces sleepiness as assessed by MSLT in healthy young subjects, independent of disease-related sleep dysfunction.
Collapse
Affiliation(s)
- Joëlle Micallef
- Clinical Investigation Centre (CIC-UPCET) and Department of Clinical Pharmacology, UMR-CNRS 6193 Institute of Cognitive Neurosciences, CHU Timone, Marseille, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Regueme SC, Barthèlemy J, Gauthier GM, Blin O, Nicol C. Delayed influence of stretch-shortening cycle fatigue on large ankle joint position coded with static positional signals. Scand J Med Sci Sports 2008; 18:373-82. [DOI: 10.1111/j.1600-0838.2007.00693.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
40
|
|
41
|
|
42
|
|
43
|
|
44
|
Cassé-Perrot C, Fakra E, Jouve E, Blin O. [Conceptualisation and validation of the "Emotional State Questionnaire (ESQ)": evaluation of an emotional profile]. Encephale 2007; 33:169-78. [PMID: 17675912 DOI: 10.1016/s0013-7006(07)91547-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVES The objective of this study is to evaluate the validity of a new self questionnaire: the "ESQ" (Emotional State Questionnaire). BACKGROUND This novel instrument possesses a number of original attributes: first of all, it is designed to assess a general emotional profile, in opposition to other similar scales which can only be applied to the emotional reactions provoked by specific stimuli. Secondly, this scale is composed of several emotional dimensions. The ESQ has been constructed according to four components: recognition, expression, internal emotional experience and social context. The first three dimensions were selected because of their wide use through behavioral experiments. Indeed, contrary to most scales used in this field, which only assess the emotional experience, we wanted to propose an instrument also able to assess the subject's impression of his own capacities to encode and decode emotions. We hypothesized that these three dimensions could not be dissociated from a fourth dimension, the social context, which therefore also figures in this scale. The emotions explored were the five fundamental emotions indicated by Izard (fear, happiness, sadness, disgust and surprise) to which we added a neutral feeling that we considered as a basic emotion. STUDY DESIGN To establish this instrument, a first conceptual phase was conducted by a group of experts. These experts all worked in the psychological field. They proposed the scale on the base of their clinical experience and after study of the literature. The scale was then validated in a population of 218 healthy volunteers, aged between 15 and 88 years. Subjects were not included if they presented depression (score above 16 in the Beck Depression Scale) or pathological anxiety (score above 5 in the Spieberger State Anxiety Inventory). The psychometric characteristics tested were: the item analysis, the item-dimension correlation, the factor analysis and the internal consistency reliability. RESULTS The population studied was equally distributed according to gender (sex ratio: 0.97), the mean age was of 36.2 2 +/- 16.1 years. Acceptability was good with less than 5% of data missing. The analysis of items revealed no floor or ceiling effect and a low correlation between items. Item-dimension correlation ranged from 0.23 to 0.62, with most scores above 0.4. The items were always better correlated to their dimension than to other dimensions, except for one item. The 4 dimensions (recognition, expression, internal emotional experience and social context of emotions) explained 42% of the total variance. Finally, the scale showed good internal consistency with Cronbach coefficients, equal or above 0.84 for the total score, the recognition and the expression dimensions. This coefficient reached 0.77 for the feeling dimension but only 0.58 for the social context dimension. CONCLUSION All together, results showed satisfactory characteristics in regard of the complexity of the notion measured. However, an important drawback is the lack of an external instrument to assess convergent validity. This instrument can be of great interest in the emotional characterization of healthy volunteers. More-over, if validated in psychiatric populations, this scale could be most useful in psychopathological assessment and also in comparison with behavioral evaluations of emotion.
Collapse
Affiliation(s)
- C Cassé-Perrot
- Centre de Pharmacologie Clinique et Evaluations Thérapeutiques, Institut des Neurosciences Cognitives de la Méditerranée, Faculté de Médecine, UMR 6193 CNRS, Université de la Méditerranée, AP-HP de Marseille, Hôpital de la Timone, 13385 Marseille cedex 5
| | | | | | | |
Collapse
|
45
|
Massol J, Puech A, Boissel JP, Alperovitch A, Bamberger M, Begaud B, Blin O, Blin P, Breart G, Brun Strang C, Buyse M, Castot A, Chauvenet M, Chicoye A, David N, De Bels F, De Sahb Berkovitch R, Dohin E, Fagnani F, Falissard B, Gastaldi-Menager C, Giri I, Haim M, Joubert J, Lapeyre-Mestre M, Lassale C, Marchant Ramirez I, Meyer F, Micallef J, Mollimard M, Moreau-Defarges T, Pazart L, Perret L, Pigeon M, Rumeau Pichon C, Tcheng P, Woler M, Zanetti L, Zylberman M. How to Anticipate the Assessment of the Public Health Benefit of New Medicines? Therapie 2007; 62:427-35. [DOI: 10.2515/therapie:2007071] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2007] [Indexed: 11/20/2022]
|
46
|
Massol J, Puech A, Boissel JP, Alperovitch A, Bamberger M, Bégaud B, Blin O, Blin P, Bréart G, Brun Strang C, Buyse M, Castot A, Chauvenet M, Chicoye A, David N, De Bels F, De Sahb Berkovitch R, Dohin E, Fagnani F, Falissard B, Gastaldi-Menager C, Giri I, Haim M, Joubert J, Lapeyre-Mestre M, Lassale C, Marchant Ramirez I, Meyer F, Micallef J, Mollimard M, Moreau-Defarges T, Pazart L, Perret L, Pigeon M, Rumeau Pichon C, Tcheng P, Woler M, Zanetti L, Zylberman M. Comment anticiper l’évaluation de l’intérêt de santé publique des médicaments ? Therapie 2007; 62:417-25. [DOI: 10.2515/therapie:2007072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2007] [Accepted: 10/05/2007] [Indexed: 11/20/2022]
|
47
|
Salgado-Pineda P, Caclin A, Baeza I, Junqué C, Bernardo M, Blin O, Fonlupt P. Schizophrenia and frontal cortex: where does it fail? Schizophr Res 2007; 91:73-81. [PMID: 17303390 DOI: 10.1016/j.schres.2006.12.028] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2006] [Revised: 12/20/2006] [Accepted: 12/21/2006] [Indexed: 10/23/2022]
Abstract
Schizophrenia is characterized by cognitive, social, and emotional impairments and by psychotic symptoms. Neuroimaging studies have reported abnormalities within the prefrontal cortex and it has been hypothesized that schizophrenia results from poor or miswired anatomical/functional connections. We have compared the functional connectivity within the frontal cortex in control and schizophrenic subjects during the realization of a Continuous Performance Task. The connectivity pattern within the frontal cortex was uncovered by the analysis of the correlation matrix computed from the fMRI time series in frontal areas for 14 schizophrenic patients and 14 control subjects. In control subjects, the right dorsolateral prefrontal cortex (DLFCr) activity correlated i) positively with the left dorsolateral prefrontal cortex and the posterior part of the supplementary motor area, ii) negatively with the medial and anterior/inferior part of the frontal cortex. In the schizophrenic group, these relations were abolished or strongly lowered. The negative relation between the DLFCr and the medial frontal cortex has been proposed to play a key role in setting a harmonious balance between the direction of attention to the external world and the expression of the individual believes and self-referential activities, and therefore, the impaired relation of right DLFCr with other frontal areas could explain a distorted perception of external world in relation with internal motivations.
Collapse
Affiliation(s)
- P Salgado-Pineda
- Institut des Neurosciences Cognitives de la Méditerranée, Faculté de Médecine, Université de la Méditerranée, UMR 6193 CNRS, Marseille, F-13385, France
| | | | | | | | | | | | | |
Collapse
|
48
|
Affiliation(s)
- T Augy
- Service de Pharmacie, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, 13395 Marseille cedex 5
| | | | | |
Collapse
|
49
|
Abstract
INTRODUCTION Depression is common in people with schizophrenia and is associated with substantial morbidity explaining also the considerable attention and recognition of this entity as suggested by the inclusion of the post-psychotic depression in DSM IV and ICD 10. The prevalence of this disorder varies according to the type of approach used (range between 7% to 75%). Prescription of antidepressants plus antipsychotic treatment is frequent in clinical practice (11 to 43%). BACKGROUND Pharmacokinetic and metabolic interactions have been identified. The cytochrome P450 has been identified as being implicated in the metabolism of most psychotropics, mainly through the CYP1A2, CYP2C19, CYP2D6, CYP3A4 isoenzymes. Tricyclic antidepressants are likely to increase chlorpromazine plasma levels. Similarly, antipsychotics such as perphenazine, chlorpromazine or haloperidol can increase antidepressant plasma levels, through the inhibition of CYP 450 isoenzymes (CYP2D6). Most of the Specific Serotonin Recapture Inhibitors (SSRIs) are likely to inhibit one or several CYP450 isoenzymes. The inhibition is moderate to marked for CYP1A2 (fluvoxamine and fluoxetine), CYP2C19 (fluoxetine, fluvoxamine and sertraline), CYP2D6 (paroxetine, fluoxetine and sertraline), and CYP3A4 (fluvoxamine, fluoxetine and sertraline). In the US, one-fourth of psychiatrists report the use of depression-rating scales in schizophrenic patients. Non specific scales (Hamilton Depression Rating Scale or Beck Depression Inventory) are the most commonly used in spite of the fact that these scales do not allow the distinction of depressive from negative symptoms in schizophrenic patients. LITERATURE FINDINGS Due to these limitations, more specific assessment tools for depressive symptoms in schizophrenia are required. Two specific scales for assessing depressive symptoms in schizophrenic patients have been constructed and validated. The Calgary Depression Scale (CDS) is a nine item scale, each item scored from 0 to 3. This scale was derived from the HDRS and the Present State Examination. Factor analysis showed that the CDS is unidimensional, has high internal consistency, and significant strong correlation with scores on the HDRS, Beck and BPRS depression scales. The CDS has been validated in different languages (Brazilian, Danish, French...). It has been shown that there is no overlap between negative or extrapyramidal and depressive symptoms assessed by the PDS in schizophrenic patients. The Psychotic Depression Scale (PDS) is a 32 item scale derived from the HDRS, PANSS, CPRS and AMDP, each item being rated from 0 to 7. A principal component analysis of the PDS items using a Varimax rotation disclosed 8 orthogonal components that account for 71% of the variance. These components involved the following dimensions : depressive mood, inhibition, vegetative signs, paranoid signs, strangeness of thought, inverse vegetative signs, guilt feelings and cognitive signs. The analysis revealed that the 'depressive mood' factor of the PDS was correlated with the 'depressive' factor and was slightly correlated with the cognitive factor of the PANSS. This first factor was not correlated with either the "negative" factor of the PANSS, or the Positive or Excitement factor of the PANSS. Hence, this PDS, factor distinguished depressive signs from negative symptoms. Due to their metrologic properties, specific scales should be preferred. However, only one open trial (of an antipsychotic) and two double blind controlled trials (one comparison of 2 antipsychotics and one comparison of an cholinesterase inhibitor versus placebo) have been published using the CDS. Likewise, only one double blind controlled trial using the PDS (comparison of 2 antipsychotics) has been published. No study of the effect of antidepressants in depressed schizophrenic patients has been published, using either the CDS or the PDS assessment criteria. DISCUSSION These specific scales are rarely used in clinical practice. Only about 1% of the US psychiatrists reported the use of the Calgary Depression Scale. Several open clinical trials have assessed the efficacy of antidepressant agents added to antipsychotic in patients with schizophrenia. They have produced inconsistent results but have suffered from methodological limits (short duration of the studies, non homogeneous inclusion criteria, heterogeneous assessment methods...). Due to the lack of a reference drug, double blind placebo-controlled trial are necessary. A recent meta-analysis has been performed on results of trials that have investigated the clinical efficacy of antidepressant medication (either tricyclics, SSRIs or others) in the treatment of depression in schizophrenic patients. In a subset of 5 trials (209 patients), the proportion improved in the antidepressant group was 26% (95% CI 10 to 42) higher than in the placebo group. The estimated number needed to treat was 4. In a subgroup of 6 studies (267 patients), the standardized mean difference on the HDRS score was -0.27 (95% CI - 0.7 to -0.2). There was no evidence that antidepressant treatment induced a deterioration of psychotic symptoms in these trials. CONCLUSION The results provide weak evidence for the efficacy of antidepressants in patients with schizophrenia and depression. Today, the only SSRI tested in the treatment of depression in schizophrenic patients is sertraline. One study led to positive results. Since the meta-analysis, one additional study has been performed comparing sertraline to placebo. No difference between the 2 treatment groups was demonstrated but the power of the trial was rather low. Further research is required to determine the best approach towards treating depression in patients with schizophrenia, with clinical trials performed for longer periods, using appropriate assessment criteria such as depressive symptoms and quality of life.
Collapse
Affiliation(s)
- J Micallef
- CPCET et Pharmacologie Clinique, Institut des Neurosciences Cognitives de la Mediterranée, Faculté de Médecine, UMR 6193, CNRS, Université de la Méditerranée, Assistance Publique - Hôpitaux de Marseille, Hôpital de la Timone, 13385 Marseille cedex 5
| | | | | |
Collapse
|
50
|
Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21:139-49. [PMID: 16625522 DOI: 10.1002/hup.757] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Adjustment Disorders With Anxiety (ADWA) account for almost 10% of psychologically motivated consultations in primary care. The aim of this double-blind randomised parallel group study was to compare (non-inferiority test) the efficacies of etifoxine, a non-benzodiazepine anxiolytic drug, and lorazepam, a benzodiazepine, for ADWA outpatients followed by general practitioners. 191 outpatients (mean age: 43, female: 66%) were assigned to receive etifoxine (50 mg tid) or lorazepam (0.5-0.5-1 mg /day) for 28 days. Efficacy was evaluated on days 7 and 28 of the treatment. The main efficacy assessment criterion was the Hamilton Rating Scale for Anxiety score (HAM-A) on Day 28 adjusted to Day 0. The anxiolytic effect of etifoxine was found not inferior to that of lorazepam (HAM-A score decrease: 54.6% vs 52.3%, respectively, p=0.0006). The two drugs were equivalent on Day 28. However, more etifoxine recipients responded to the treatment (HAM-A score decreased by >or=50%, p=0.03). Clinical improvement (based on Clinical Global Impression scale CGI, Social Adjustment Scale Self-Report SAS-SR, and Sheehan scores) was observed in both treatment arms, but more etifoxine patients improved markedly (p=0.03) and had a marked therapeutic effect without side effects as assessed by CGI, p=0.04. Moreover, 1 week after stopping treatment, fewer patients taking etifoxine experienced a rebound of anxiety, compared to lorazepam (1 and 8, respectively, p=0.034).
Collapse
Affiliation(s)
- N Nguyen
- CPCET et Pharmacologie Clinique, Institut des Neurosciences Cognitives de la Méditerranée, Faculté de Médecine, UMR CNRS Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille-Hôpital de la Timone, 13385 Marseille Cedex 5, France
| | | | | | | | | | | | | | | |
Collapse
|